Free Trial
NASDAQ:TECH

Bio-Techne Q4 2025 Earnings Report

Bio-Techne logo
$55.19 +2.60 (+4.94%)
As of 11:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bio-Techne EPS Results

Actual EPS
N/A
Consensus EPS
$0.49
Beat/Miss
N/A
One Year Ago EPS
N/A

Bio-Techne Revenue Results

Actual Revenue
N/A
Expected Revenue
$315.14 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bio-Techne Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
9:30AM ET

Conference Call Resources

Bio-Techne Earnings Headlines

How a Kansas farm boy gained 1,285% in two days
A former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a meme stock. It was a pattern called “Crossfire” — a 3-step setup you can execute in a normal brokerage app. Master trader Jeff Clark is now revealing how it works in a free 30-minute video, available for a limited time.
See More Bio-Techne Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bio-Techne? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bio-Techne and other key companies, straight to your email.

About Bio-Techne

Bio-Techne (NASDAQ:TECH)oration (NASDAQ:TECH) is a global provider of life science reagents, instruments and services that support research, diagnostics and bioprocessing applications. The company’s offerings include cytokines, growth factors, immunoassays, antibodies, enzymes, proteins and nucleic acid reagents designed to enable scientists to quantify, characterize and manipulate biological systems. Bio-Techne’s portfolio also incorporates advanced instrumentation platforms for protein analysis, cell analysis, digital PCR and spatial biology.

Through its core brands—such as R&D Systems, Novus Biologicals, Tocris, ProteinSimple and Advanced Cell Diagnostics—Bio-Techne serves a diverse customer base spanning academic and government research institutions, biotechnology and pharmaceutical companies, clinical laboratories and biomanufacturers. The company’s products are used in basic research, drug discovery, biomarker identification, therapeutic development, personalized medicine and quality control in biologics manufacturing.

Since its founding in 1976, Bio-Techne has expanded both organically and through strategic acquisitions to broaden its technological capabilities and geographic reach. Key acquisitions have included ProteinSimple in 2014, which added microfluidic and capillary electrophoresis platforms, and Advanced Cell Diagnostics in 2019, which bolstered the company’s spatial biology and in situ hybridization offerings. Headquartered in Minneapolis, Minnesota, Bio-Techne maintains research, manufacturing and distribution sites across North America, Europe and Asia.

Under the leadership of President and Chief Executive Officer Charles Kummeth, Bio-Techne emphasizes innovation, customer support and strategic investment in emerging life science technologies. The company’s senior management team and board of directors draw on extensive industry experience to guide growth initiatives, foster partnerships with academic and commercial organizations, and invest in next-generation tools for proteomics, genomics and cell analysis.

View Bio-Techne Profile

More Earnings Resources from MarketBeat